Page 29 - Read Online

Selvakumar et al. Multikinase inhibitors as neo-adjuvants in HCC

scan and serum AFP revealed good tumor response of any personal information of patients.
in the form of clearing of portal vein thrombosis and
reduction of AFP. Ethics approval
This is not needed as it is not an experimental study.
These two cases give us additional hope that PVT
is not the end of the story in HCC patients. Though REFERENCES
today the standard of care for HCC with PVTT is
EBRT followed by reassessment and transplantation 1. Marrero JA, Welling T. Modern diagnosis and management of
[6]
once tumor thrombus clears. We believe that hepatocellular carcinoma. Clin Liver Dis 2009;13:233-47.
sorafenib plays definite role as a neoadjuvant therapy. 2. Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS,
Guettier C, Vallee JC, Saliba F, Bismuth H, Samuel D, Castaing
In conclusion, high AFP and major vascular invasion D, Adam R. Salvage versus primary liver transplantation for early
should not be considered as end points in treatment hepatocellular carcinoma: do both strategies yield similar outcomes?
of HCC patients. Neoadjuvant modalities are to be Ann Surg 2016;264:155-63.
employed followed by reevaluation for transplantation. 3. Asham EH, Boktour M, Ghobrial RM. Liver transplantation for
Since final conclusion needs high experience with hepatocellular carcinoma: past, present, and future. Clin Transpl
more number of cases individual discretion is advised 2012:173-83.
before offering transplantation in these patients. 4. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr,
Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The
impact of pre-operative loco-regional therapy on outcome after
Financial support and sponsorship liver transplantation for hepatocellular carcinoma. Am J Transplant
None. 2005;5:795-804.
5. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P,
Conflicts of interest Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular
There are no conflicts of interest. carcinoma before liver transplantation: a cost-benefit analysis while
awaiting data on sorafenib safety. Hepatology 2010;51:165-73.
6. Lee DS, Seong J. Radiotherapeutics options for hepatocellular
Patient consent carcinoma with portal vein tumor thrombosis. Liver Cancer
Patient consent is not needed as there is no disclosure 2014;3:18-30.

Hepatoma Research ¦ Volume 3 ¦ January 12, 2017 21